

July 2025



Jim Joyce
CEO, Inventor

FORWARD-LOOKING STATEMENTS

The following presentation is for informational purposes only and is not an offer to sell or a solicitation of an offer to buy any securities of Sigyn Therapeutics, Inc. ("Sigyn"). All statements in this presentation, other than statements of historical fact, are forward-looking statements within the meaning of federal securities laws. In some cases, you can identify forward-looking statements by terms such as "may," "will," "expect," "plan," "anticipate," "strategy," "designed," "intend," "believe," "estimate," "target," or "potential" and other similar expressions. Forward-looking statements involve risks, uncertainties and assumptions that may cause Sigyn's actual results, performance, or achievements to be materially different from those expressed or implied by the forward-looking statements in this presentation, including risks and uncertainties inherent in Sigyn's business and other risks described in Sigyn's filings with the Securities and Exchange Commission (SEC). Sigyn's forward-looking statements are based upon its current expectations and involve assumptions that may never materialize or may prove to be incorrect. All forward-looking statements are expressly qualified in their entirety by these cautionary statements. Further information regarding these and other risks is included under the heading "Risk Factors" in Sigyn's periodic reports filed with the SEC, which are available on the SEC's website. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they were made. Sigyn undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.

A close-up photograph of a medical device, likely a dialyzer or blood purifier. It features a clear plastic cylindrical body with a blue cap on top. A red tube is connected to the top, and a white tube with a yellow connector is attached to the side. The background is blurred, showing other medical equipment.

Next-Generation Blood Purification Therapies

Focus is the Creation of Value Through Clinical Progression

- Sigyn Therapy™ addresses life-threatening inflammatory disorders - including sepsis, the #1 cause of hospital deaths - \$62 billion annual cost to U.S. Healthcare system


Joint Venture Initiatives to Optimize the Benefit of Cancer Therapies

- ChemoPrep™ to improve chemotherapy delivery and reduce toxicity - most widely administered drug to treat cancer (<1% currently delivered to intended cancer targets)
- ImmunePrep™ to improve delivery of immunotherapeutic antibodies - top selling class of cancer drugs - 2024 revenues ~\$125 billion (<1% currently delivered to intended targets)

5-year objective to be acquired

The Sigyn Team

- Includes extracorporeal industry thought leaders across Management, the Company's Board of Directors and Science Advisory Board
- Management oversaw development of first blood purification device to receive two FDA Breakthrough Designations and the first device to receive FDA market clearance to treat a pandemic virus (Ebola). TIME magazine named the device a "Top 25 Invention" & "Top 11 Medical Breakthrough." Also included among management is the inventor of a hemoadsorption system that received CE Mark clearance and was subsequently registered in 32 countries to treat inflammatory related conditions.



First-in-Mammal Studies at University of Michigan


Sigyn Therapy™

Designed to address life-threatening inflammatory disorders with no FDA-approved treatments

Notable Blood Purification Therapies Being Advanced by Public Companies

- CytoSorb Cytokine Clearance Device (CytoSorbents Corporation)
- PMX Endotoxin Clearance Device (Spectral Medical) *Current Market Cap ~\$250m*
- The Hemopurifier – Broad-Spectrum Clearance of Viral Pathogens (Aethlon Medical)

*“Wouldn’t it be nice if there was one device
that could address all these targets?”*



Sigyn Therapy™

One Device Able to Address

- Inflammatory Cytokines
- Bacterial Toxins (including endotoxin)
- Viral Pathogens



Sigyn Therapy™

First-In-Industry Attributes

- Deployed on dialysis and CRRT machines already located in hospitals and clinics
- Highly Efficient – bloodstream processed ~15 times during a four-hour treatment
- Immense Capacity - incorporates an adsorbent formulation with ~200,000 M² of surface area (50 acres)



Sigyn Therapy™

FDA Breakthrough Device Initiatives

Target Treatment Indications:

- Sepsis
- Endotoxemia w/ concurrent inflammation in End-Stage Renal Disease (ESRD) patients

Criterion for a FDA Breakthrough Device Designation

- ✓ Offers a treatment for a life-threatening or irreversibly debilitating human disease or condition
- ✓ No approved or cleared alternatives exist
- ✓ Device availability is in the best interest of patients

End-Stage Renal Disease (ESRD) Endotoxemia & Inflammation

- 550,000+ ESRD patients receive ~85 million dialysis treatments in the U.S. each year
- Annual mortality rate is ~20%
- Cardiovascular Disease & Sepsis are leading causes of early death (~70%)
- Endotoxemia and concurrent inflammation drive these conditions

Potential Value to the Dialysis Industry?

Two Organizations Dominate The U.S. Dialysis Industry



- **~200,000 U.S. ESRD patients**
- **Average annual revenue per-patient is ~\$60,000**
- **~\$1 Billion** of increased revenue per-month of extended ESRD patient life
- **~\$250 million** in recouped revenues per-week of reduced hospitalization




- ~280,000 U.S. ESRD patients
- Average annual revenue per-patient is ~\$62,000
- ~\$1.45 Billion in increased revenue per-month of extended ESRD patient life
- ~\$362 million in recouped revenues per-week of reduced hospitalization



Clinical Plan

- Investigation Device Exemption (IDE) drafted for FDA submission
- Feasibility study protocol to enroll 12-15 ESRD subjects at three site locations
- Sigyn Therapy to be administered in series with regular dialysis treatments
- Primary endpoint is safety / Secondary endpoints - change in endotoxin and inflammatory cytokine levels
- Value inflection point - study completion sets stage for ESRD subject pivotal study and provides a pathway into non-ESRD indications

Modular Feasibility Study Provides Potential Pathway into Market Enabling Studies



Multiple Commercialization Opportunities to Treat Rare Disease Disorders

~\$250M – The Market Cap of a Company Advancing an Endotoxin Depletion Device

Oncology

"We don't develop drugs to treat cancer. We develop devices to improve the benefit of drugs to treat cancer"



Joint Venture Initiatives to Optimize the Benefit of Cancer Therapies

ChemoPrep™

- ChemoPrep™ is designed to improve delivery and reduce toxicity of chemotherapy, the most widely administered drug to treat cancer (<1% of chemotherapy doses are delivered to intended cancer targets)
- ChemoPrep™ is an adsorption technology to reduce the circulating presence of tumor-derived exosomes that interfere with chemotherapy delivery, extract chemotherapy out of tumor cells, and promote treatment resistance.
- Therapeutic goal is to maintain treatment effectiveness with lower doses. Thus, reducing treatment toxicity

Joint Venture Initiatives to Optimize the Benefit of Cancer Therapies

ImmunePrep™

- ImmunePrep™ is a platform technology to improve the delivery of immunotherapeutic antibodies, the top selling class of cancer drugs with revenues of ~\$125 billion in 2024 (<1% of immunotherapeutic antibody doses are delivered to intended targets)
- Delivery is limited by high concentrations of circulating decoys that display the antigen binding site of the antibody. As a result, most patients don't respond to therapy.
- ImmunePrep™ products incorporate a therapeutic antibody to sweep circulating decoys from the bloodstream prior to the subsequent infusion of the antibody into the cancer patient. A “REVERSE DECOY” mechanism of action.

Public Market Data

- OTCQB: SIGY
- Recent Price: \$2.75
- 52-Week Range: \$2.49 - \$5.75
- Shares Outstanding: 1,605,377
- >90% of Shares Outstanding held by management, two funds, and one angel investment group

A close-up photograph of a medical device, likely a blood purifier or dialyzer. It features a clear plastic cylindrical body with a blue cap and a yellow connector. Red and white medical tubing are connected to the device. The background is blurred, showing more of the device and tubing.

Next-Generation Blood Purification Therapies

Focus is the Creation of Value Through Clinical Progression

- Sigyn Therapy™ addresses life-threatening inflammatory disorders - including sepsis, the #1 cause of hospital deaths - \$62 billion annual cost to U.S. Healthcare system

Joint Venture Initiatives to Optimize the Benefit of Cancer Therapies

- ChemoPrep™ to improve chemotherapy delivery and reduce toxicity - most widely administered drug to treat cancer (<1% currently delivered to intended cancer targets)
- ImmunePrep™ to improve delivery of immunotherapeutic antibodies - top selling class of cancer drugs - 2024 revenues ~\$125 billion (<1% currently delivered to intended targets)

5-year objective to be acquired



*2468 Historic Decatur Road, Suite 140
San Diego, California 92106*

SigynTherapeutics.com